Boon T - Search Results

1

Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.

Boon T. Boon T. Int J Cancer. 1993 May 8;54(2):177-80. doi: 10.1002/ijc.2910540202. Int J Cancer. 1993. PMID: 8486420 Review. No abstract available.

2

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells.

Carrasco J, Van Pel A, Neyns B, Lethé B, Brasseur F, Renkvist N, van der Bruggen P, van Baren N, Paulus R, Thielemans K, Boon T, Godelaine D. Carrasco J, et al. Among authors: boon t. J Immunol. 2008 Mar 1;180(5):3585-93. doi: 10.4049/jimmunol.180.5.3585. J Immunol. 2008. PMID: 18292586 Clinical Trial.

3

A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma.

Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG. Takenoyama M, et al. Among authors: boon t. Int J Cancer. 2006 Apr 15;118(8):1992-7. doi: 10.1002/ijc.21594. Int J Cancer. 2006. PMID: 16287085

4

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: boon t. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Clinical Trial.

5

A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.

Ottaviani S, Zhang Y, Boon T, van der Bruggen P. Ottaviani S, et al. Among authors: boon t. Cancer Immunol Immunother. 2005 Dec;54(12):1214-20. doi: 10.1007/s00262-005-0705-2. Epub 2005 Jul 16. Cancer Immunol Immunother. 2005. PMID: 16025263

6

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N. Cipponi A, et al. Among authors: boon t. Cancer Res. 2012 Aug 15;72(16):3997-4007. doi: 10.1158/0008-5472.CAN-12-1377. Epub 2012 Jul 31. Cancer Res. 2012. PMID: 22850419

7

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Lurquin C, et al. Among authors: boon t. J Exp Med. 2005 Jan 17;201(2):249-57. doi: 10.1084/jem.20041378. J Exp Med. 2005. PMID: 15657294 Free PMC article.

8

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Coulie PG, et al. Among authors: boon t. Nat Rev Cancer. 2014 Feb;14(2):135-46. doi: 10.1038/nrc3670. Nat Rev Cancer. 2014. PMID: 24457417 Review.

9

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Coulie PG, et al. Among authors: boon t. Immunol Rev. 2002 Oct;188:33-42. doi: 10.1034/j.1600-065x.2002.18804.x. Immunol Rev. 2002. PMID: 12445279 Review.

10

Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells.

Loriot A, De Plaen E, Boon T, De Smet C. Loriot A, et al. Among authors: boon t. J Biol Chem. 2006 Apr 14;281(15):10118-26. doi: 10.1074/jbc.M510469200. Epub 2006 Feb 22. J Biol Chem. 2006. PMID: 16497664

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results